JP6743051B2 - Ｃｄ１ｄを標的とする単一ドメイン抗体 - Google Patents
Ｃｄ１ｄを標的とする単一ドメイン抗体 Download PDFInfo
- Publication number
- JP6743051B2 JP6743051B2 JP2017557264A JP2017557264A JP6743051B2 JP 6743051 B2 JP6743051 B2 JP 6743051B2 JP 2017557264 A JP2017557264 A JP 2017557264A JP 2017557264 A JP2017557264 A JP 2017557264A JP 6743051 B2 JP6743051 B2 JP 6743051B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cd1d
- single domain
- seq
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010003723 Single-Domain Antibodies Proteins 0.000 title claims description 135
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 title description 4
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 title description 4
- 230000008685 targeting Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 145
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 69
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 69
- 210000004027 cell Anatomy 0.000 claims description 64
- 241000282414 Homo sapiens Species 0.000 claims description 54
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims description 31
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 29
- 230000004913 activation Effects 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 230000020411 cell activation Effects 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 229930186217 Glycolipid Natural products 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims description 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 77
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 77
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 64
- 230000027455 binding Effects 0.000 description 25
- 239000003981 vehicle Substances 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 17
- 238000000684 flow cytometry Methods 0.000 description 16
- 230000006698 induction Effects 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 11
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 11
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 11
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 11
- 108090000672 Annexin A5 Proteins 0.000 description 10
- 102000004121 Annexin A5 Human genes 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000016396 cytokine production Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000035800 maturation Effects 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 235000002198 Annona diversifolia Nutrition 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 241000282842 Lama glama Species 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- -1 tens Chemical class 0.000 description 4
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 229960002385 streptomycin sulfate Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OKTWQKXBJUBAKS-WQADZSDSSA-N 2-[[(e,2r,3s)-2-amino-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC\C=C\[C@H](O)[C@H](N)COP(O)(=O)OCC[N+](C)(C)C OKTWQKXBJUBAKS-WQADZSDSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 101100203200 Danio rerio shha gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- RWHPBLFPAUXKDB-FSBZVHFBSA-N N-octanoylisoglobotriaosyl ceramide Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 RWHPBLFPAUXKDB-FSBZVHFBSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- MYYARUCLXARAEE-ZATZPJRKSA-N alpha-C-GalCer Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CC[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCCCCC MYYARUCLXARAEE-ZATZPJRKSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2014192 | 2015-01-27 | ||
| NL2014192 | 2015-01-27 | ||
| PCT/NL2016/050064 WO2016122320A1 (en) | 2015-01-27 | 2016-01-27 | Single domain antibodies targeting cd1d |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127379A Division JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508229A JP2018508229A (ja) | 2018-03-29 |
| JP2018508229A5 JP2018508229A5 (enExample) | 2019-03-07 |
| JP6743051B2 true JP6743051B2 (ja) | 2020-08-19 |
Family
ID=52630466
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557264A Active JP6743051B2 (ja) | 2015-01-27 | 2016-01-27 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
| JP2020127379A Active JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020127379A Active JP7165701B2 (ja) | 2015-01-27 | 2020-07-28 | Ｃｄ１ｄを標的とする単一ドメイン抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10501541B2 (enExample) |
| EP (1) | EP3250608B1 (enExample) |
| JP (2) | JP6743051B2 (enExample) |
| KR (2) | KR102574729B1 (enExample) |
| CN (2) | CN107531787B (enExample) |
| AU (2) | AU2016212777B2 (enExample) |
| CA (1) | CA2975078A1 (enExample) |
| EA (1) | EA201791691A1 (enExample) |
| MX (1) | MX386714B (enExample) |
| SG (1) | SG11201706128PA (enExample) |
| WO (1) | WO2016122320A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102574729B1 (ko) | 2015-01-27 | 2023-09-04 | 라바 테라퓨틱스 엔.브이. | Cd1d를 표적화하는 단일 도메인 항체 |
| US12077586B2 (en) | 2018-09-19 | 2024-09-03 | LAVA Therapeutics N.V. | Bispecific antibodies for use in the treatment of hematological malignancies |
| WO2020113063A1 (en) * | 2018-11-30 | 2020-06-04 | Aleta Biotherapeutics Inc. | Single domain antibodies against cll-1 |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| IL305579A (en) | 2021-03-01 | 2023-10-01 | Deciduous Therapeutics Inc | Compounds for activating invariant natural killer T cells and methods for use in eliminating inflammatory senescent cells |
| EP4419109A1 (en) | 2021-10-21 | 2024-08-28 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
| CN116217723A (zh) * | 2021-12-22 | 2023-06-06 | 北京世纪沃德生物科技有限公司 | 一种crp驼源单域抗体及其制备方法和应用 |
| EP4285926A1 (en) * | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| WO2024256586A1 (en) | 2023-06-14 | 2024-12-19 | LAVA Therapeutics N.V. | Cd1d antibodies and methods of use |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2698880B1 (fr) | 1992-11-25 | 1995-02-24 | Inst Nat Sante Rech Med | Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques. |
| DK0751780T3 (da) | 1993-06-21 | 2003-10-13 | Brigham & Womens Hospital | Fremgangsmåder til isolering af CD1-fremviste antigener, vacciner, som omfatter CD1-fremviste antigener, og cellelinier til anvendelse i nævnte fremgangsmåder |
| WO2000046383A2 (en) | 1999-02-05 | 2000-08-10 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
| EP1198572A2 (en) | 1999-08-02 | 2002-04-24 | Keygene N.V. | Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
| US6737398B1 (en) | 1999-09-30 | 2004-05-18 | National Jewish Medical And Research Center | Modulation of γδ T cells to regulate airway hyperresponsiveness |
| WO2001022816A1 (en) | 1999-09-30 | 2001-04-05 | National Jewish Medical And Research Center | MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS |
| AU2001259230A1 (en) | 2000-04-28 | 2001-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions |
| PT1297017E (pt) | 2000-06-19 | 2012-09-04 | Gen Hospital Corp | Composições e métodos de anticorpos monoclonais e policlonais específicos para subpopulações de célula t |
| CA2441893C (en) | 2001-03-26 | 2015-01-20 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
| US8178098B2 (en) | 2001-04-03 | 2012-05-15 | National Jewish Health | Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies |
| CN100522999C (zh) | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
| EP1532175B1 (en) | 2002-03-22 | 2012-10-17 | Aprogen, Inc. | Humanized antibody and process for preparing the same |
| US8084020B2 (en) * | 2002-05-01 | 2011-12-27 | Beth Israel Deaconess Medical Center | Use of anti-CD1 antibodies for the modulation of immune responses |
| JP2006512910A (ja) | 2002-10-23 | 2006-04-20 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | Ａ３４およびａ３３様３ｄｎａ、タンパク質、それらに対する抗体、ならびに同一物を使用した治療方法 |
| US9028816B2 (en) | 2003-01-10 | 2015-05-12 | Ablynx N.V. | Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor |
| WO2005046711A2 (en) | 2003-11-07 | 2005-05-26 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Stimulation or inhibition of gamma delta t-cells to promote or inhibit bone healing |
| EP1753783B1 (en) | 2004-06-03 | 2014-08-06 | Novimmune SA | Anti-cd3 antibodies and methods of use thereof |
| US8153426B2 (en) | 2004-08-19 | 2012-04-10 | University College Cardiff Consultants Limited | Preparation of antigen-presenting human gamma-delta T cells and use in immunotherapy |
| US7682614B2 (en) | 2004-11-02 | 2010-03-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for inhibition of NKT cells |
| US8338173B2 (en) | 2005-08-11 | 2012-12-25 | University College Cardiff Consultants Limited | Preparation of antigen-presenting human γδ T cells and use in immunotherapy |
| ES2780176T3 (es) * | 2006-02-22 | 2020-08-24 | Riken | Inmunoterapia mediante la utilización de células capaces de co-expresar un antígeno diana y CD1d y pulsadas con un ligando de CD1d |
| GB0605247D0 (en) * | 2006-03-15 | 2006-04-26 | Chiron Srl | Compositions and methods for immunisation |
| EP1878440A1 (en) | 2006-07-13 | 2008-01-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds |
| US8012484B2 (en) | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
| EP2058388A1 (en) * | 2007-10-05 | 2009-05-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non-conventional NKT cells for use in cancer therapy |
| WO2010130830A2 (en) * | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders |
| AU2012323781B8 (en) * | 2011-10-14 | 2015-05-14 | Teva Pharmaceuticals Australia Pty Ltd. | Antibodies to CD1d |
| US9670275B2 (en) | 2012-01-23 | 2017-06-06 | Ablynx N.V. | Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| CN104334741B (zh) | 2012-03-28 | 2018-08-17 | 歌德塔有限公司 | 组合的γ9δ2T细胞受体链交换 |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014210522A1 (en) | 2013-06-28 | 2014-12-31 | The Scripps Research Institute | Nkt cell ligands and methods of use |
| WO2015121383A1 (en) | 2014-02-12 | 2015-08-20 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| KR102601469B1 (ko) | 2014-04-10 | 2023-11-14 | 라바 테라퓨틱스 엔.브이. | 인간 Vγ9Vδ2 T 세포에 결합하는 면역글로불린 |
| JP6894702B2 (ja) | 2014-05-13 | 2021-06-30 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子 |
| CA2988504A1 (en) | 2014-07-02 | 2016-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for diagnosing and treating cd1d restricted gamma/delta t cell lymphomas |
| WO2016081518A2 (en) | 2014-11-17 | 2016-05-26 | Adicet Bio, Inc. | Engineered gamma delta t-cells |
| KR102574729B1 (ko) | 2015-01-27 | 2023-09-04 | 라바 테라퓨틱스 엔.브이. | Cd1d를 표적화하는 단일 도메인 항체 |
| CN104829730A (zh) | 2015-04-14 | 2015-08-12 | 苏静 | 一种能联合免疫细胞增强肿瘤杀伤能力的双特异性抗体及其制备方法和应用 |
| US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| CN109195992A (zh) | 2016-04-29 | 2019-01-11 | 本康生物制药（深圳）有限公司 | 多特异性结合偶联物、相关的药物组合物及应用 |
| US20180028566A1 (en) | 2016-07-29 | 2018-02-01 | New York University | Gamma delta t cells as a target for treatment of solid tumors |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| TWI687227B (zh) | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| US20210163620A1 (en) | 2018-04-05 | 2021-06-03 | Brian Granda | Trispecific binding molecules against cancers and uses thereof |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| JP2022521751A (ja) | 2019-02-21 | 2022-04-12 | マレンゴ・セラピューティクス，インコーポレーテッド | 抗ｔｃｒ抗体分子およびその使用 |
| AU2020267504A1 (en) | 2019-05-08 | 2021-12-02 | Janssen Biotech, Inc. | Materials and methods for modulating T cell mediated immunity |
| KR20220045980A (ko) | 2019-08-16 | 2022-04-13 | 감마델타 테라퓨틱스 리미티드 | 체외 감마 델타 t 세포 집단 |
| WO2021032963A1 (en) | 2019-08-16 | 2021-02-25 | GammaDelta Therapeutics Limited | Therapeutic uses of anti-tcr delta variable 1 antibodies |
| AU2021225870A1 (en) | 2020-02-27 | 2022-10-20 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| UY39127A (es) | 2020-03-13 | 2021-09-30 | Janssen Biotech Inc | Materiales y métodos para modular la inmunidad mediada por cadena delta |
| CN116390950A (zh) | 2020-10-28 | 2023-07-04 | 詹森生物科技公司 | 用于调节δγ链介导的免疫的组合物和方法 |
-
2016
- 2016-01-27 KR KR1020177024072A patent/KR102574729B1/ko active Active
- 2016-01-27 EA EA201791691A patent/EA201791691A1/ru unknown
- 2016-01-27 CA CA2975078A patent/CA2975078A1/en active Pending
- 2016-01-27 US US15/546,406 patent/US10501541B2/en active Active
- 2016-01-27 KR KR1020237029643A patent/KR20230132604A/ko active Pending
- 2016-01-27 SG SG11201706128PA patent/SG11201706128PA/en unknown
- 2016-01-27 AU AU2016212777A patent/AU2016212777B2/en not_active Revoked
- 2016-01-27 EP EP16715360.0A patent/EP3250608B1/en not_active Revoked
- 2016-01-27 CN CN201680007612.0A patent/CN107531787B/zh not_active Withdrawn - After Issue
- 2016-01-27 MX MX2017009680A patent/MX386714B/es unknown
- 2016-01-27 WO PCT/NL2016/050064 patent/WO2016122320A1/en not_active Ceased
- 2016-01-27 CN CN202111671891.XA patent/CN114504645A/zh active Pending
- 2016-01-27 JP JP2017557264A patent/JP6743051B2/ja active Active
-
2019
- 2019-10-29 US US16/666,734 patent/US11591394B2/en active Active
-
2020
- 2020-07-28 JP JP2020127379A patent/JP7165701B2/ja active Active
-
2022
- 2022-02-11 AU AU2022200922A patent/AU2022200922A1/en not_active Withdrawn
-
2023
- 2023-01-30 US US18/161,163 patent/US12110328B2/en active Active
-
2024
- 2024-09-03 US US18/822,745 patent/US20240425592A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022200922A1 (en) | 2022-03-03 |
| JP2020172550A (ja) | 2020-10-22 |
| US10501541B2 (en) | 2019-12-10 |
| EP3250608B1 (en) | 2024-08-21 |
| MX2017009680A (es) | 2018-04-13 |
| US20240425592A1 (en) | 2024-12-26 |
| AU2016212777B2 (en) | 2021-11-18 |
| EP3250608A1 (en) | 2017-12-06 |
| CN107531787A (zh) | 2018-01-02 |
| HK1247937A1 (en) | 2018-10-05 |
| US12110328B2 (en) | 2024-10-08 |
| US20240067726A1 (en) | 2024-02-29 |
| US20180142020A1 (en) | 2018-05-24 |
| CA2975078A1 (en) | 2016-08-04 |
| KR20170128254A (ko) | 2017-11-22 |
| AU2016212777A1 (en) | 2017-08-17 |
| KR20230132604A (ko) | 2023-09-15 |
| CN114504645A (zh) | 2022-05-17 |
| WO2016122320A1 (en) | 2016-08-04 |
| JP2018508229A (ja) | 2018-03-29 |
| KR102574729B1 (ko) | 2023-09-04 |
| MX386714B (es) | 2025-03-11 |
| JP7165701B2 (ja) | 2022-11-04 |
| US20200115450A1 (en) | 2020-04-16 |
| CN107531787B (zh) | 2022-01-18 |
| US11591394B2 (en) | 2023-02-28 |
| SG11201706128PA (en) | 2017-08-30 |
| EA201791691A1 (ru) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7165701B2 (ja) | Ｃｄ１ｄを標的とする単一ドメイン抗体 | |
| ES2963598T3 (es) | Dominios de unión al antígeno humanizado contra CD19 y métodos de uso | |
| TWI688401B (zh) | 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合 | |
| EP3858856A1 (en) | Anti-b7-h3 monoclonal antibody and use thereof in cell therapy | |
| CN113272325A (zh) | 双作用CD1d免疫球蛋白 | |
| KR20240090732A (ko) | 항-pvrig 항체 및 사용 방법 | |
| US20230167185A1 (en) | Cd40 binding protein | |
| CN116731169B (zh) | 一种分拣蛋白1特异性的纳米抗体及其应用 | |
| US20240374644A1 (en) | Herv-k antibody therapeutics | |
| JP2020501518A (ja) | キメラタンパク質を用いたアレルギー疾患の治療 | |
| EP4458956A1 (en) | Anti-mesothelin nanobody chimeric antigen receptor and use thereof | |
| HK1247937B (en) | Single domain antibodies targeting cd1d | |
| EA042112B1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| US20200024347A1 (en) | Or10h1 antigen binding proteins and uses thereof | |
| JP2024517985A (ja) | 抗－ＣＤ３００ｃモノクローナル抗体及びその癌の予防または治療用バイオマーカー | |
| CN118488961A (zh) | Herv-k抗体、细胞、疫苗及药物治疗剂 | |
| JP2024517986A (ja) | 抗－ＣＤ３００ｃ抗体を利用した併用療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190125 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190125 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191024 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191111 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200309 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200515 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200629 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200729 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6743051 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S801 | Written request for registration of abandonment of right |
Free format text: JAPANESE INTERMEDIATE CODE: R311801 |
|
| ABAN | Cancellation due to abandonment | ||
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |